Adalimumab
Top View
- Golimumab: a New Anti-TNF Agent on the Horizon for Inflammatory Arthritis
- International Nonproprietary Names (Inn) for Biological and Biotechnological Substances
- (INN) for Biological and Biotechnological Substances
- Humira), Adalimumab-Atto (Amjevita
- Adalimumab (Humira®) Is an Antibody Against a Pro-Inflammatory Protein (Cytokine) Called Tumor Necrosis Factor Α (Anti-TNF)
- WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
- WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
- CIMZIA (Certolizumab Pegol) for Injection, for Subcutaneous Use CIMZIA (Certolizumab Pegol) Injection, for Subcutaneous Use ------CONTRAINDICATIONS------ Initial U.S
- (12) United States Patent (10) Patent No.: US 9,446,134 B2 Maggio (45) Date of Patent: *Sep
- Adalimumab Level with Reflex to Adalimumab Antibody
- Successful Treatment of Hidradenitis Suppurativa in the Setting of Crohn Disease with Combination Adalimumab and Ustekinumab
- CLINICAL PROTOCOL HGS1006-C1113 Protocol Amendment: 03 Eudract Number: 2011-005667-25 Date: 22 MAY 2017
- Inhibition of Membrane-Bound BAFF by the Anti-BAFF Antibody Belimumab
- Comparative Efficacy Between Adalimumab and Infliximab in The
- Biologic Therapy for Posterior Uveitis and Panuveitis by Sirichai Pasadhika, MD; Eric B
- HUMIRA® (Adalimumab) Injection, for Subcutaneous Use • Administered by Subcutaneous Injection (2) Initial U.S
- Crohn's Disease – Infliximab
- Customs Tariff - Schedule Xxi - 1